Remap-Cap Trial Says No Evidence Of Harm Associated With The Administration Of Convalescent Plasma In Covid-19 Patients

REMAP-CAP TRIAL SAYS NO EVIDENCE OF HARM ASSOCIATED WITH THE ADMINISTRATION OF CONVALESCENT PLASMA IN COVID-19 PATIENTS